<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00978120</url>
  </required_header>
  <id_info>
    <org_study_id>DAIT-AAIB-flu-001</org_study_id>
    <nct_id>NCT00978120</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of an H1N1 Influenza Vaccine in People With Asthma</brief_title>
  <official_title>A Phase II Study in Patients With Asthma to Assess the Safety and Immunogenicity of an Unadjuvanted Novartis H1N1 Influenza Vaccine Administered at Two Dose Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and the body's immune response (body's
      defense against disease) to an experimental H1N1 influenza vaccine in people with asthma. The
      study will enroll 350, and possibly up to 400 healthy adults ages 12 and older with mild,
      moderate, or severe asthma. Participants will be randomly assigned to 1 of 2 possible vaccine
      groups: group 1 will receive 15 mcg of H1N1 vaccine; group 2 will receive 30 mcg of H1N1
      vaccine given as two 15 mcg injections. Both groups will receive vaccine injections on days 0
      and 21.

      Study procedures include: medical history, physical exam, spirometry, maintaining a memory
      aid and, and blood sample collection. Participants will be involved in study related
      procedures for approximately 7 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A new swine-origin influenza A/H1N1 virus was recently identified as a significant cause of
      respiratory illness in Mexico and the United States. In response, the World Health
      Organization (WHO) declared a pandemic on June 11, 2009. Current data indicates that licensed
      seasonal influenza vaccines are not likely to provide protection against the new H1N1 virus.
      Development and deployment of a vaccine for the new H1N1 virus, particularly to at-risk
      populations, is essential.

      Groups at risk for influenza yearly include the elderly and those with asthma, and current
      guidelines from the Advisory Committee on Immunization Practices (ACIP) recommend vaccination
      of adults and children with asthma. Early, unpublished data on US patients hospitalized by
      H1N1 infection indicates that many had underlying asthma, and it is expected people with
      asthma will be on a priority list for H1N1 influenza vaccination. Data also indicate that
      increased dosage of vaccines may increase development of antibodies and that use of certain
      inhalers may affect immunization. This study will test the safety and immunogenicity of an
      unadjuvanted, inactivated H1N1 vaccine at two dosage levels in people with asthma.

      Participation in this study will last approximately 34 weeks. Participants will be stratified
      into two groups: those with mild to moderate versus those with severe asthma. All
      participants will be randomly assigned to receive either a high dose (30 mcg) or low dose (15
      mcg) H1N1 vaccine. Both vaccine dosages will be administered in two intramuscular injections
      21 days apart. Participants assigned to the higher dose (30 mcg) will receive two injections
      of the 15 mcg vaccine at each administration.

      Participants will complete study visits at entry, administration of the vaccines on Days 1
      and 21, follow-ups a week after each vaccine injection, and 21 days after the second
      injection. Measurements at these visits will include spirometry (measurement of air entering
      and leaving the lungs), a questionnaire about asthma, a targeted physical examination, an
      adverse event and medication assessment, inspection of vaccination site, and collection of a
      blood sample. A urine sample will be collected for pregnancy test before each vaccination. In
      additions, for 8 days after each vaccination injection participants will keep a diary
      recording oral temperature, adverse events, asthma symptoms, and use of inhalers. These
      diaries will be reviewed at study visits. Participants will also receive follow-up phone
      calls to assess safety 60, 120, and 180 days after the last vaccine injection.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Serious Adverse Events (SAEs) Attributed To Vaccination</measure>
    <time_frame>Measured at Baseline Visit and Days 1, 8, 21, 28, 41, 80, 120, and 201</time_frame>
    <description>Percentage of participants with serious adverse events (SAEs) attributed to vaccination, as determined by site investigators at the time of reporting.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Reactogenicity Adverse Events (AEs) Status Post Vaccine 1</measure>
    <time_frame>Days 1 through 8</time_frame>
    <description>Percentage of participants with reactogenicity AEs, local (erythema, ecchymosis, induration, pain and tenderness at the injection sites) and systemic (feverishness, chills, fatigue, myalgias, arthralgias, headache and nausea), within 8 Days After Vaccination 1 by Dose Level Group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Reactogenicity Adverse Events (AEs) Status Post Vaccine 2</measure>
    <time_frame>Days 21 through 28</time_frame>
    <description>Percentage of participants with reactogenicity AEs, local (erythema, ecchymosis, induration, pain and tenderness at the injection sites) and systemic (feverishness, chills, fatigue, myalgias, arthralgias, headache and nausea), within 8 Days After Vaccination 2 by Dose Level Group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Asthma Exacerbations Status Post Vaccine 1</measure>
    <time_frame>Days 1 to 8</time_frame>
    <description>Percentage of participants with asthma exacerbations within 8 days after vaccination 1. Any of the following events are considered asthma exacerbation: Increase in the daily use of bronchodilator rescue medication for 2 consecutive days; an increase is defined as ≥6puffs of bronchodilator from a metered-dose inhaler or ≥2 uses of nebulized albuterol above average use reported in the two weeks prior to Visit 1. Increase in use of systemic corticosteroids or the addition of systemic corticosteroids to treatment regimen for asthma. Unscheduled use of health care for the treatment of asthma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Asthma Exacerbations Status Post Vaccination 2</measure>
    <time_frame>Days 21 to 28</time_frame>
    <description>Percentage of participants with asthma exacerbations within 8 days after vaccination 2. Any of the following events are considered asthma exacerbation: Increase in the daily use of bronchodilator rescue medication for 2 consecutive days; an increase is defined as ≥6puffs of bronchodilator from a metered-dose inhaler or ≥2 uses of nebulized albuterol above average use reported in the two weeks prior to Visit 1. Increase in use of systemic corticosteroids or the addition of systemic corticosteroids to treatment regimen for asthma. Unscheduled use of health care for the treatment of asthma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Seroconversion at Day 28 Following Two Administrations of Vaccination, Mild-Moderate Asthmatics</measure>
    <time_frame>Days 1 to 28</time_frame>
    <description>Seroconversion: The percentage of participants with a four-fold or greater hemagglutination inhibition assay (HAI) antibody titer increase compared to baseline against the novel influenza hemagglutinin type 1 and neuraminidase type 1 (H1N1) 2009 virus following two administrations of Novartis H1N1 vaccine at each dose, combined across age groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Seroconversion at Day 28 Following Two Administrations of Vaccination, Severe Asthmatics</measure>
    <time_frame>Days 1 to 28</time_frame>
    <description>Seroconversion: The percentage of participants with a four-fold or greater hemagglutination inhibition assay (HAI) antibody titer increase compared to baseline against the novel influenza hemagglutinin type 1 and neuraminidase type 1 (H1N1) 2009 virus following two administrations of Novartis H1N1 vaccine at each dose, combined across age groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Seroconversion at Day 41 Following Two Administrations of Vaccination, Mild-Moderate Asthmatics</measure>
    <time_frame>Days 1 to 41</time_frame>
    <description>Seroconversion: The percentage of participants with a four-fold or greater hemagglutination inhibition assay (HAI) antibody titer increase compared to baseline against the novel influenza hemagglutinin type 1 and neuraminidase type 1 (H1N1) 2009 virus following two administrations of Novartis H1N1 vaccine at each dose, combined across age groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Seroconversion at Day 41 Following Two Administrations of Vaccination, Severe Asthmatics</measure>
    <time_frame>Days 1 to 41</time_frame>
    <description>Seroconversion: The percentage of participants with a four-fold or greater hemagglutination inhibition assay (HAI) antibody titer increase compared to baseline against the novel influenza hemagglutinin type 1 and neuraminidase type 1 (H1N1) 2009 virus following two administrations of Novartis H1N1 vaccine at each dose, combined across age groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Seroprotection at Day 28 Following Two Administrations of Vaccination, Mild-Moderate Asthmatics</measure>
    <time_frame>Days 1 to 28</time_frame>
    <description>Seroprotection: The percentage of participants with a hemagglutination inhibition assay (HAI) antibody titer of 1:40 or greater against influenza H1N1 2009 virus following two administrations of the H1N1 vaccine at each dose, combined across age groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Seroprotection at Day 28 Following Two Administrations of Vaccination, Severe Asthmatics</measure>
    <time_frame>Days 1 to 28</time_frame>
    <description>Percentage of participants with seroprotection defined as a hemagglutination inhibition assay (HAI) antibody titer of 1:40 or greater against influenza H1N1 2009 virus following two administrations of the H1N1 vaccine at each dose, combined across age groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Seroprotection at Day 41 Following Two Administrations of Vaccination, Mild-Moderate Asthmatics</measure>
    <time_frame>Days 1 to 41</time_frame>
    <description>Percentage of participants with seroprotection defined as a hemagglutination inhibition assay (HAI) antibody titer of 1:40 or greater against influenza H1N1 2009 virus following two administrations of the H1N1 vaccine at each dose, combined across age groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Seroprotection at Day 41 Following Two Administrations of Vaccination, Severe Asthmatics</measure>
    <time_frame>Days 1 to 41</time_frame>
    <description>Percentage of participants with seroprotection defined as a hemagglutination inhibition assay (HAI) antibody titer of 1:40 or greater against influenza H1N1 2009 virus following two administrations of the H1N1 vaccine at each dose, combined across age groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroconversion at Day 21 Following Single Administration of Vaccination, Mild-Moderate Asthmatics</measure>
    <time_frame>Days 1 to 21</time_frame>
    <description>Percentage of participants with seroconversion defined as a four-fold or greater hemagglutination inhibition assay (HAI) antibody titer increase compared to baseline against the novel influenza hemagglutinin type 1 and neuraminidase type 1 (H1N1) 2009 virus following a single administration of Novartis H1N1 vaccine at each dose, combined across age groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroconversion at Day 21 Following Single Administration of Vaccination, Severe Asthmatics</measure>
    <time_frame>Days 1 to 21</time_frame>
    <description>Percentage of participants with seroconversion defined as a four-fold or greater hemagglutination inhibition assay(HAI) antibody titer increase compared to baseline against the novel influenza hemagglutinin type 1 and neuraminidase type 1 (H1N1) 2009 virus following a single administration of Novartis H1N1 vaccine at each dose, combined across age groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroprotection at Day 21 Following Single Administration of Vaccination, Mild-Moderate Asthmatics</measure>
    <time_frame>Days 1 to 21</time_frame>
    <description>Percentage of participants with seroprotection defined as hemagglutination inhibition assay (HAI) antibody titer of 1:40 or greater against influenza H1N1 2009 virus following a single administration of the H1N1 vaccine at each dose, combined across age groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroprotection at Day 21 Following Single Administration of Vaccination, Severe Asthmatics</measure>
    <time_frame>Days 1 to 21</time_frame>
    <description>Percentage of participants with seroprotection defined as hemagglutination inhibition assay (HAI) antibody titer of 1:40 or greater against influenza H1N1 2009 virus following a single administration of the H1N1 vaccine at each dose, combined across age groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">390</enrollment>
  <condition>H1N1 Influenza Virus</condition>
  <arm_group>
    <arm_group_label>H1N1 vaccine high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be stratified according to asthma severity and will receive the high dosage of the H1N1 vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>H1N1 vaccine low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be stratified according to asthma severity and will receive the low dosage of the H1N1 vaccine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>H1N1 vaccine high dose</intervention_name>
    <description>30 mcg of unadjuvanted Novartis H1N1 vaccine delivered as two, 15 micrograms (mcg), intramuscular injections. Each 30 mcg dose is administered 21 days apart.</description>
    <arm_group_label>H1N1 vaccine high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>H1N1 vaccine low dose</intervention_name>
    <description>15 mcg of unadjuvanted Novartis H1N1 vaccine delivered in two intramuscular injections 21 days apart</description>
    <arm_group_label>H1N1 vaccine low dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of mild/moderate or severe asthma according to Severe Asthma Research
             Project (SARP) definitions and either a SARP participant or having prior participation
             in the studies or clinics of the investigators

          -  Males and females age 12 (inclusive) and older

          -  Females of child-bearing potential must not be pregnant and must agree to practice
             adequate contraception that may include, but is not limited to: abstinence, monogamous
             relationship with vasectomized partner, barrier methods such as condoms, diaphragms,
             spermicides, intrauterine devices, and licensed hormonal methods during the study for
             at least 30 days following the last vaccination.

          -  Able to understand and comply with planned study procedures

          -  Will provide written informed consent and assent (if age appropriate) prior to
             initiation of any study procedures

        Exclusion Criteria:

          -  Allergy to eggs or other components of the vaccine, including gelatin, formaldehyde,
             octoxinol, thimerosal, and chicken protein

          -  Positive urine pregnancy test within 24 hours prior to vaccination, if a female of
             childbearing potential

          -  Currently breastfeeding

          -  History of smoking 20 pack-years or greater (current or former smokers with a history
             of less than 20 pack-years can be included in the study)

          -  Has been previously diagnosed by a physician with chronic obstructive pulmonary
             disease, chronic bronchitis, emphysema, or cystic fibrosis

          -  Has received anticancer chemotherapy or radiation therapy (cytotoxic) within the past
             36 months

          -  Has an active neoplastic disease or a history of any hematologic malignancy

          -  Has a diagnosis of schizophrenia, bipolar disease, or other major psychiatric
             diagnosis

          -  Has been hospitalized for psychiatric illness, history of suicide attempt, or
             confinement for danger to self or others within the past 10 years

          -  Receiving psychiatric drugs (subjects who are receiving a single antidepressant drug
             and are stable for at least 3 months prior to study entry, without de-compensating
             symptoms, will be allowed to enroll)

          -  History of receiving immunoglobulin, including anti-cytokine antibodies, or other
             blood product within the 3 months prior to vaccination in this study

          -  Has received an experimental agent (vaccine, drug, biologic, device, blood product, or
             medication) within 1 month prior to vaccination in this study or expect to receive an
             experimental agent during this study (prior to the Day 141 follow-up call - 100 days
             after the second vaccination)

          -  Has received any live licensed vaccines within 4 weeks or inactivated licensed
             vaccines within 2 weeks prior to vaccination in this study, or plan receipt of such
             vaccines within 21 days following the second vaccination

          -  Has a history of severe reactions following previous immunization with influenza virus
             vaccines

          -  Has an acute illness, including an oral temperature greater than 100.4°F, within 1
             week of either vaccination

          -  Has a chronic neurologic or autoimmune disorder

          -  Has a history of Guillain-Barré Syndrome

          -  Has an acute or chronic medical condition that, in the opinion of the investigator,
             would render vaccination unsafe, or would interfere with the evaluation of vaccine
             response

          -  Has an ongoing asthma exacerbation or had an asthma exacerbation that was resolved
             less than 7 days prior to vaccination

          -  Has any condition that would, in the opinion of the site investigator, place the
             participant at an unacceptable risk of injury, render the participant unable to meet
             the requirements of the protocol, or interfere with the successful completion of the
             study.

          -  Participated in a novel influenza H1N1 2009 vaccine study in the past two years or has
             a history of novel influenza H1N1 2009 infection or treatment

          -  Has known active HIV, Hepatitis B or Hepatitis C infection

          -  Has a history of alcohol or drug abuse in the last 5 years

          -  Plans to travel outside of North America in the time between the first vaccination and
             42 days following the first vaccination

          -  Does not speak English primarily
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Busse, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University School of Medicine</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Asthma Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team, Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, Garten RJ, Gubareva LV, Xu X, Bridges CB, Uyeki TM. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med. 2009 Jun 18;360(25):2605-15. doi: 10.1056/NEJMoa0903810. Epub 2009 May 7. Erratum in: N Engl J Med. 2009 Jul 2;361(1):102.</citation>
    <PMID>19423869</PMID>
  </reference>
  <reference>
    <citation>Patriarca PA, Cox NJ. Influenza pandemic preparedness plan for the United States. J Infect Dis. 1997 Aug;176 Suppl 1:S4-7.</citation>
    <PMID>9240686</PMID>
  </reference>
  <reference>
    <citation>Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society. Am J Respir Crit Care Med. 2000 Dec;162(6):2341-51. Review.</citation>
    <PMID>11112161</PMID>
  </reference>
  <results_reference>
    <citation>Busse WW, Peters SP, Fenton MJ, Mitchell H, Bleecker ER, Castro M, Wenzel S, Erzurum SC, Fitzpatrick AM, Teague WG, Jarjour N, Moore WC, Sumino K, Simeone S, Ratanamaneechat S, Penugonda M, Gaston B, Ross TM, Sigelman S, Schiepan JR, Zaccaro DJ, Crevar CJ, Carter DM, Togias A. Vaccination of patients with mild and severe asthma with a 2009 pandemic H1N1 influenza virus vaccine. J Allergy Clin Immunol. 2011 Jan;127(1):130-7, 137.e1-3. doi: 10.1016/j.jaci.2010.11.014. Epub 2010 Dec 9.</citation>
    <PMID>21145578</PMID>
  </results_reference>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2009</study_first_submitted>
  <study_first_submitted_qc>September 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2009</study_first_posted>
  <results_first_submitted>June 27, 2012</results_first_submitted>
  <results_first_submitted_qc>June 27, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 6, 2012</results_first_posted>
  <last_update_submitted>August 8, 2012</last_update_submitted>
  <last_update_submitted_qc>August 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza A Virus, H1N1 Subtype</keyword>
  <keyword>Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study participants were recruited from October 16 to November 13, 2009 at the seven National Heart, Lung, and Blood Institute (NHLBI)- funded Severe Asthma Research Program sites.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Mild/Moderate Asthma, Low Dose Vaccine (15mcg)</title>
          <description>Participants with mild-to-moderate asthma received one 15 micrograms (mcg) dose of unadjuvanted,[1] inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injection on Day 1 and Day 21.</description>
        </group>
        <group group_id="P2">
          <title>Mild/Moderate Asthma, High Dose Vaccine (30mcg)</title>
          <description>Participants with mild-to-moderate asthma received two 15 mcg doses of unadjuvanted,[1] inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injections on Day 1 and Day 21.</description>
        </group>
        <group group_id="P3">
          <title>Severe Asthma, Low Dose Vaccine (15mcg)</title>
          <description>Participants with severe asthma received one 15 mcg dose of unadjuvanted,[1] inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injection on Day 1 and Day 21.</description>
        </group>
        <group group_id="P4">
          <title>Severe Asthma, High Dose Vaccine (30mcg)</title>
          <description>Participants with severe asthma received two 15 mcg doses of unadjuvanted,[1] inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injections on Day 1 and Day 21.
[1] Unadjuvanted: No agents added to, or used in conjunction with, vaccine antigens to augment or potentiate (and possibly target) the specific immune response to the antigen. (U.S. Food And Drug Administration)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="110"/>
                <participants group_id="P2" count="107"/>
                <participants group_id="P3" count="87"/>
                <participants group_id="P4" count="86"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="108"/>
                <participants group_id="P2" count="107"/>
                <participants group_id="P3" count="84"/>
                <participants group_id="P4" count="84"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved out of state</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mild/Moderate Asthma, Low Dose Vaccine (15mcg)</title>
          <description>Participants with mild-to-moderate asthma received one 15 micrograms (mcg) dose of unadjuvanted,[1] inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injection on Day 1 and Day 21.</description>
        </group>
        <group group_id="B2">
          <title>Mild/Moderate Asthma, High Dose Vaccine (30mcg)</title>
          <description>Participants with mild-to-moderate asthma received two 15 mcg doses of unadjuvanted,[1] inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injections on Day 1 and Day 21.</description>
        </group>
        <group group_id="B3">
          <title>Severe Asthma, Low Dose Vaccine (15mcg)</title>
          <description>Participants with severe asthma received one 15 mcg dose of unadjuvanted,[1] inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injection on Day 1 and Day 21.</description>
        </group>
        <group group_id="B4">
          <title>Severe Asthma, High Dose Vaccine (30mcg)</title>
          <description>Participants with severe asthma received two 15 mcg doses of unadjuvanted,[1] inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injections on Day 1 and Day 21.
[1] Unadjuvanted: No agents added to, or used in conjunction with, vaccine antigens to augment or potentiate (and possibly target) the specific immune response to the antigen. (U.S. Food And Drug Administration)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="110"/>
            <count group_id="B2" value="107"/>
            <count group_id="B3" value="87"/>
            <count group_id="B4" value="86"/>
            <count group_id="B5" value="390"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="67"/>
                    <measurement group_id="B4" value="68"/>
                    <measurement group_id="B5" value="294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.1" spread="18.1"/>
                    <measurement group_id="B2" value="36.3" spread="17.0"/>
                    <measurement group_id="B3" value="45.2" spread="17.0"/>
                    <measurement group_id="B4" value="46.5" spread="17.3"/>
                    <measurement group_id="B5" value="41.3" spread="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="45"/>
                    <measurement group_id="B5" value="231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="41"/>
                    <measurement group_id="B5" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="87"/>
                    <measurement group_id="B4" value="86"/>
                    <measurement group_id="B5" value="390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age at Asthma Onset</title>
          <description>The age at asthma onset is the age defined in years when the participant was told by a physician that he/she has asthma. This was calculated by subtracting the participant’s age at the baseline visit (visit 1) from the number of years the participant reported to have known having asthma.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.1" spread="17.0"/>
                    <measurement group_id="B2" value="16.4" spread="14.9"/>
                    <measurement group_id="B3" value="21.9" spread="19.7"/>
                    <measurement group_id="B4" value="21.9" spread="20.1"/>
                    <measurement group_id="B5" value="19.0" spread="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Asthma Duration</title>
          <description>Asthma duration is the number of years since the participant was told by a physician that he/she has asthma as reported at the baseline visit, visit 1.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.9" spread="13.9"/>
                    <measurement group_id="B2" value="19.9" spread="13.4"/>
                    <measurement group_id="B3" value="23.3" spread="16.5"/>
                    <measurement group_id="B4" value="24.6" spread="17.8"/>
                    <measurement group_id="B5" value="22.3" spread="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>BMI is a number calculated from a person’s height and weight that provides a reliable indicator of body fatness for most people. Higher values reflect greater amount of body fat. [1] In adults, a BMI less than 18.5 is underweight; 18.5 to 24.9 is a normal or healthy weight; greater than or equal to 25.0 is overweight. The height and weight was collected at baseline only.
[1]: Healthy Weight , Assessing Your Weight , Body Mass Index http://www.cdc.gov/healthyweight/assessing/bmi/index.html</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.5" spread="8.5"/>
                    <measurement group_id="B2" value="28.5" spread="6.8"/>
                    <measurement group_id="B3" value="31.8" spread="9.7"/>
                    <measurement group_id="B4" value="30.1" spread="8.0"/>
                    <measurement group_id="B5" value="29.9" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Forced Expiratory Volume in 1 second (FEV1) % Predicted</title>
          <description>FEV1 is air volume exhaled in 1 second during spirometry. Asthma severity classification for trial: mild--pre-bronchodilator FEV1 ≥ 80% predicted requiring no/ low-moderate dose of inhaled glucocorticoids; moderate--pre-bronchodilator FEV1 &lt;80% predicted requiring no/ low-moderate dose of inhaled glucocorticoids; severe--requiring high-dose inhaled glucocorticoids with/without continuous/near continuous oral glucocorticoids, or uncontrolled despite treatment. FEV1 percent of predicted value is FEV1 converted to a percentage of normal, based on height, weight, and race.</description>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83.8" spread="16.3"/>
                    <measurement group_id="B2" value="86.6" spread="17.6"/>
                    <measurement group_id="B3" value="72.6" spread="19.4"/>
                    <measurement group_id="B4" value="69.8" spread="20.8"/>
                    <measurement group_id="B5" value="79.0" spread="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Forced Vital Capacity (FVC) % Predicted</title>
          <description>FVC is a lung function test that measures the total amount of air exhaled. The percent of predicted value is FVC converted to a percentage of normal, based on height, weight, and race. Estimates of severity of abnormalities in flow volume measured by FVC: Mild-65-80% of predicted value; Moderate-50-65% of predicted value; Severe-&lt;50% of predicted value.</description>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92.6" spread="14.3"/>
                    <measurement group_id="B2" value="94.3" spread="16.1"/>
                    <measurement group_id="B3" value="85.0" spread="17.1"/>
                    <measurement group_id="B4" value="80.9" spread="18.7"/>
                    <measurement group_id="B5" value="88.8" spread="17.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FEV1/FVC Ratio</title>
          <description>The FEV1 (forced expiratory volume 1))/ FVC (forced vital capacity) ratio is used to evaluate airways obstructions since pure restrictive ventilatory defects cause an equal reduction in the FEV1 and the FVC. An FEV1/FVC ratio below 80% indicates airflow obstruction. Normal FEV1/FVC: 8 – 19 years of age=85%; 20-39 years of age=80%; 40- 59 years of age 75%; 60-80 years of age 70% [1]
[1]: National Asthma Education and Prevention Program Expert Panel Report 3, Guidelines for the Diagnosis and Management of Asthma. Oct. 2007. http://www.nhlbi.nih.gov/guidelines/asthma/asthsumm.pdf</description>
          <units>Ratio (x 100)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.5" spread="9.07"/>
                    <measurement group_id="B2" value="75.7" spread="8.99"/>
                    <measurement group_id="B3" value="68.4" spread="10.91"/>
                    <measurement group_id="B4" value="68.4" spread="11.76"/>
                    <measurement group_id="B5" value="72.1" spread="10.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Serious Adverse Events (SAEs) Attributed To Vaccination</title>
        <description>Percentage of participants with serious adverse events (SAEs) attributed to vaccination, as determined by site investigators at the time of reporting.</description>
        <time_frame>Measured at Baseline Visit and Days 1, 8, 21, 28, 41, 80, 120, and 201</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mild/Moderate Asthma, Low Dose Vaccine (15mcg)</title>
            <description>Participants with mild-to-moderate asthma received one 15 micrograms (mcg) dose of unadjuvanted,[1] inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injection on Day 1 and Day 21.</description>
          </group>
          <group group_id="O2">
            <title>Mild/Moderate Asthma, High Dose Vaccine (30mcg)</title>
            <description>Participants with mild-to-moderate asthma received two 15 mcg doses of unadjuvanted,[1] inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injections on Day 1 and Day 21.</description>
          </group>
          <group group_id="O3">
            <title>Severe Asthma, Low Dose Vaccine (15mcg)</title>
            <description>Participants with severe asthma received one 15 mcg dose of unadjuvanted,[1] inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injection on Day 1 and Day 21.</description>
          </group>
          <group group_id="O4">
            <title>Severe Asthma, High Dose Vaccine (30mcg)</title>
            <description>Participants with severe asthma received two 15 mcg doses of unadjuvanted,[1] inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injections on Day 1 and Day 21.
[1] Unadjuvanted: No agents added to, or used in conjunction with, vaccine antigens to augment or potentiate (and possibly target) the specific immune response to the antigen. (U.S. Food And Drug Administration)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Serious Adverse Events (SAEs) Attributed To Vaccination</title>
          <description>Percentage of participants with serious adverse events (SAEs) attributed to vaccination, as determined by site investigators at the time of reporting.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Reactogenicity Adverse Events (AEs) Status Post Vaccine 1</title>
        <description>Percentage of participants with reactogenicity AEs, local (erythema, ecchymosis, induration, pain and tenderness at the injection sites) and systemic (feverishness, chills, fatigue, myalgias, arthralgias, headache and nausea), within 8 Days After Vaccination 1 by Dose Level Group.</description>
        <time_frame>Days 1 through 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mild/Moderate Asthma, Low Dose Vaccine (15mcg)</title>
            <description>Participants with mild-to-moderate asthma received one 15 micrograms (mcg) dose of unadjuvanted,[1] inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injection on Day 1 and Day 21.</description>
          </group>
          <group group_id="O2">
            <title>Mild/Moderate Asthma, High Dose Vaccine (30mcg)</title>
            <description>Participants with mild-to-moderate asthma received two 15 mcg doses of unadjuvanted,[1] inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injections on Day 1 and Day 21.</description>
          </group>
          <group group_id="O3">
            <title>Severe Asthma, Low Dose Vaccine (15mcg)</title>
            <description>Participants with severe asthma received one 15 mcg dose of unadjuvanted,[1] inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injection on Day 1 and Day 21.</description>
          </group>
          <group group_id="O4">
            <title>Severe Asthma, High Dose Vaccine (30mcg)</title>
            <description>Participants with severe asthma received two 15 mcg doses of unadjuvanted,[1] inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injections on Day 1 and Day 21.
[1] Unadjuvanted: No agents added to, or used in conjunction with, vaccine antigens to augment or potentiate (and possibly target) the specific immune response to the antigen. (U.S. Food And Drug Administration)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Reactogenicity Adverse Events (AEs) Status Post Vaccine 1</title>
          <description>Percentage of participants with reactogenicity AEs, local (erythema, ecchymosis, induration, pain and tenderness at the injection sites) and systemic (feverishness, chills, fatigue, myalgias, arthralgias, headache and nausea), within 8 Days After Vaccination 1 by Dose Level Group.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systemic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="63"/>
                    <measurement group_id="O3" value="64"/>
                    <measurement group_id="O4" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="54"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.014</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Reactogenicity Adverse Events (AEs) Status Post Vaccine 2</title>
        <description>Percentage of participants with reactogenicity AEs, local (erythema, ecchymosis, induration, pain and tenderness at the injection sites) and systemic (feverishness, chills, fatigue, myalgias, arthralgias, headache and nausea), within 8 Days After Vaccination 2 by Dose Level Group.</description>
        <time_frame>Days 21 through 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mild/Moderate Asthma, Low Dose Vaccine (15mcg)</title>
            <description>Participants with mild-to-moderate asthma received one 15 micrograms (mcg) dose of unadjuvanted,[1] inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injection on Day 1 and Day 21.</description>
          </group>
          <group group_id="O2">
            <title>Mild/Moderate Asthma, High Dose Vaccine (30mcg)</title>
            <description>Participants with mild-to-moderate asthma received two 15 mcg doses of unadjuvanted,[1] inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injections on Day 1 and Day 21.</description>
          </group>
          <group group_id="O3">
            <title>Severe Asthma, Low Dose Vaccine (15mcg)</title>
            <description>Participants with severe asthma received one 15 mcg dose of unadjuvanted,[1] inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injection on Day 1 and Day 21.</description>
          </group>
          <group group_id="O4">
            <title>Severe Asthma, High Dose Vaccine (30mcg)</title>
            <description>Participants with severe asthma received two 15 mcg doses of unadjuvanted,[1] inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injections on Day 1 and Day 21.
[1] Unadjuvanted: No agents added to, or used in conjunction with, vaccine antigens to augment or potentiate (and possibly target) the specific immune response to the antigen. (U.S. Food And Drug Administration)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Reactogenicity Adverse Events (AEs) Status Post Vaccine 2</title>
          <description>Percentage of participants with reactogenicity AEs, local (erythema, ecchymosis, induration, pain and tenderness at the injection sites) and systemic (feverishness, chills, fatigue, myalgias, arthralgias, headache and nausea), within 8 Days After Vaccination 2 by Dose Level Group.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systemic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="48"/>
                    <measurement group_id="O4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="60"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Asthma Exacerbations Status Post Vaccine 1</title>
        <description>Percentage of participants with asthma exacerbations within 8 days after vaccination 1. Any of the following events are considered asthma exacerbation: Increase in the daily use of bronchodilator rescue medication for 2 consecutive days; an increase is defined as ≥6puffs of bronchodilator from a metered-dose inhaler or ≥2 uses of nebulized albuterol above average use reported in the two weeks prior to Visit 1. Increase in use of systemic corticosteroids or the addition of systemic corticosteroids to treatment regimen for asthma. Unscheduled use of health care for the treatment of asthma.</description>
        <time_frame>Days 1 to 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mild/Moderate Asthma, Low Dose Vaccine (15mcg)</title>
            <description>Participants with mild-to-moderate asthma received one 15 micrograms (mcg) dose of unadjuvanted,[1] inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injection on Day 1 and Day 21.</description>
          </group>
          <group group_id="O2">
            <title>Mild/Moderate Asthma, High Dose Vaccine (30mcg)</title>
            <description>Participants with mild-to-moderate asthma received two 15 mcg doses of unadjuvanted,[1] inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injections on Day 1 and Day 21.</description>
          </group>
          <group group_id="O3">
            <title>Severe Asthma, Low Dose Vaccine (15mcg)</title>
            <description>Participants with severe asthma received one 15 mcg dose of unadjuvanted,[1] inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injection on Day 1 and Day 21.</description>
          </group>
          <group group_id="O4">
            <title>Severe Asthma, High Dose Vaccine (30mcg)</title>
            <description>Participants with severe asthma received two 15 mcg doses of unadjuvanted,[1] inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injections on Day 1 and Day 21.
[1] Unadjuvanted: No agents added to, or used in conjunction with, vaccine antigens to augment or potentiate (and possibly target) the specific immune response to the antigen. (U.S. Food And Drug Administration)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Asthma Exacerbations Status Post Vaccine 1</title>
          <description>Percentage of participants with asthma exacerbations within 8 days after vaccination 1. Any of the following events are considered asthma exacerbation: Increase in the daily use of bronchodilator rescue medication for 2 consecutive days; an increase is defined as ≥6puffs of bronchodilator from a metered-dose inhaler or ≥2 uses of nebulized albuterol above average use reported in the two weeks prior to Visit 1. Increase in use of systemic corticosteroids or the addition of systemic corticosteroids to treatment regimen for asthma. Unscheduled use of health care for the treatment of asthma.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Asthma Exacerbations Status Post Vaccination 2</title>
        <description>Percentage of participants with asthma exacerbations within 8 days after vaccination 2. Any of the following events are considered asthma exacerbation: Increase in the daily use of bronchodilator rescue medication for 2 consecutive days; an increase is defined as ≥6puffs of bronchodilator from a metered-dose inhaler or ≥2 uses of nebulized albuterol above average use reported in the two weeks prior to Visit 1. Increase in use of systemic corticosteroids or the addition of systemic corticosteroids to treatment regimen for asthma. Unscheduled use of health care for the treatment of asthma.</description>
        <time_frame>Days 21 to 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mild/Moderate Asthma, Low Dose Vaccine (15mcg)</title>
            <description>Participants with mild-to-moderate asthma received one 15 micrograms (mcg) dose of unadjuvanted,[1] inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injection on Day 1 and Day 21.</description>
          </group>
          <group group_id="O2">
            <title>Mild/Moderate Asthma, High Dose Vaccine (30mcg)</title>
            <description>Participants with mild-to-moderate asthma received two 15 mcg doses of unadjuvanted,[1] inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injections on Day 1 and Day 21.</description>
          </group>
          <group group_id="O3">
            <title>Severe Asthma, Low Dose Vaccine (15mcg)</title>
            <description>Participants with severe asthma received one 15 mcg dose of unadjuvanted,[1] inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injection on Day 1 and Day 21.</description>
          </group>
          <group group_id="O4">
            <title>Severe Asthma, High Dose Vaccine (30mcg)</title>
            <description>Participants with severe asthma received two 15 mcg doses of unadjuvanted,[1] inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injections on Day 1 and Day 21.
[1] Unadjuvanted: No agents added to, or used in conjunction with, vaccine antigens to augment or potentiate (and possibly target) the specific immune response to the antigen. (U.S. Food And Drug Administration)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Asthma Exacerbations Status Post Vaccination 2</title>
          <description>Percentage of participants with asthma exacerbations within 8 days after vaccination 2. Any of the following events are considered asthma exacerbation: Increase in the daily use of bronchodilator rescue medication for 2 consecutive days; an increase is defined as ≥6puffs of bronchodilator from a metered-dose inhaler or ≥2 uses of nebulized albuterol above average use reported in the two weeks prior to Visit 1. Increase in use of systemic corticosteroids or the addition of systemic corticosteroids to treatment regimen for asthma. Unscheduled use of health care for the treatment of asthma.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroconversion at Day 21 Following Single Administration of Vaccination, Mild-Moderate Asthmatics</title>
        <description>Percentage of participants with seroconversion defined as a four-fold or greater hemagglutination inhibition assay (HAI) antibody titer increase compared to baseline against the novel influenza hemagglutinin type 1 and neuraminidase type 1 (H1N1) 2009 virus following a single administration of Novartis H1N1 vaccine at each dose, combined across age groups.</description>
        <time_frame>Days 1 to 21</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mild/Moderate Asthma, Low Dose Vaccine (15mcg)</title>
            <description>Participants with mild-to-moderate asthma received one 15 micrograms (mcg) dose of unadjuvanted[1], inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injection on Day 1 and Day 21.</description>
          </group>
          <group group_id="O2">
            <title>Mild/Moderate Asthma, High Dose Vaccine (30mcg)</title>
            <description>Participants with mild-to-moderate asthma received two 15 mcg doses of unadjuvanted[1], inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injections on Day 1 and Day 21.
[1] Unadjuvanted: No agents added to, or used in conjunction with, vaccine antigens to augment or potentiate (and possibly target) the specific immune response to the antigen. (U.S. Food And Drug Administration)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion at Day 21 Following Single Administration of Vaccination, Mild-Moderate Asthmatics</title>
          <description>Percentage of participants with seroconversion defined as a four-fold or greater hemagglutination inhibition assay (HAI) antibody titer increase compared to baseline against the novel influenza hemagglutinin type 1 and neuraminidase type 1 (H1N1) 2009 virus following a single administration of Novartis H1N1 vaccine at each dose, combined across age groups.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.4"/>
                    <measurement group_id="O2" value="85.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.470</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroconversion at Day 21 Following Single Administration of Vaccination, Severe Asthmatics</title>
        <description>Percentage of participants with seroconversion defined as a four-fold or greater hemagglutination inhibition assay(HAI) antibody titer increase compared to baseline against the novel influenza hemagglutinin type 1 and neuraminidase type 1 (H1N1) 2009 virus following a single administration of Novartis H1N1 vaccine at each dose, combined across age groups.</description>
        <time_frame>Days 1 to 21</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Severe Asthma, Low Dose Vaccine (15mcg)</title>
            <description>Participants with severe asthma received one 15 mcg dose of unadjuvanted[1], inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injection on Day 1 and Day 21.</description>
          </group>
          <group group_id="O2">
            <title>Severe Asthma, High Dose Vaccine (30mcg)</title>
            <description>Participants with severe asthma received two 15 mcg doses of unadjuvanted[1], inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injections on Day 1 and Day 21.
[1] Unadjuvanted: No agents added to, or used in conjunction with, vaccine antigens to augment or potentiate (and possibly target) the specific immune response to the antigen. (U.S. Food And Drug Administration)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion at Day 21 Following Single Administration of Vaccination, Severe Asthmatics</title>
          <description>Percentage of participants with seroconversion defined as a four-fold or greater hemagglutination inhibition assay(HAI) antibody titer increase compared to baseline against the novel influenza hemagglutinin type 1 and neuraminidase type 1 (H1N1) 2009 virus following a single administration of Novartis H1N1 vaccine at each dose, combined across age groups.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.6"/>
                    <measurement group_id="O2" value="85.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.120</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroprotection at Day 21 Following Single Administration of Vaccination, Mild-Moderate Asthmatics</title>
        <description>Percentage of participants with seroprotection defined as hemagglutination inhibition assay (HAI) antibody titer of 1:40 or greater against influenza H1N1 2009 virus following a single administration of the H1N1 vaccine at each dose, combined across age groups.</description>
        <time_frame>Days 1 to 21</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mild/Moderate Asthma, Low Dose Vaccine (15mcg)</title>
            <description>Participants with mild-to-moderate asthma received one 15 micrograms (mcg) dose of unadjuvanted[1], inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injection on Day 1 and Day 21.</description>
          </group>
          <group group_id="O2">
            <title>Mild/Moderate Asthma, High Dose Vaccine (30mcg)</title>
            <description>Participants with mild-to-moderate asthma received two 15 mcg doses of unadjuvanted[1], inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injections on Day 1 and Day 21.
[1] Unadjuvanted: No agents added to, or used in conjunction with, vaccine antigens to augment or potentiate (and possibly target) the specific immune response to the antigen. (U.S. Food And Drug Administration)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroprotection at Day 21 Following Single Administration of Vaccination, Mild-Moderate Asthmatics</title>
          <description>Percentage of participants with seroprotection defined as hemagglutination inhibition assay (HAI) antibody titer of 1:40 or greater against influenza H1N1 2009 virus following a single administration of the H1N1 vaccine at each dose, combined across age groups.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.7"/>
                    <measurement group_id="O2" value="95.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.284</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroprotection at Day 21 Following Single Administration of Vaccination, Severe Asthmatics</title>
        <description>Percentage of participants with seroprotection defined as hemagglutination inhibition assay (HAI) antibody titer of 1:40 or greater against influenza H1N1 2009 virus following a single administration of the H1N1 vaccine at each dose, combined across age groups.</description>
        <time_frame>Days 1 to 21</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Severe Asthma, Low Dose Vaccine (15mcg)</title>
            <description>Participants with severe asthma received one 15 mcg dose of unadjuvanted[1], inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injection on Day 1 and Day 21.</description>
          </group>
          <group group_id="O2">
            <title>Severe Asthma, High Dose Vaccine (30mcg)</title>
            <description>Participants with severe asthma received two 15 mcg doses of unadjuvanted[1], inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injections on Day 1 and Day 21.
[1] Unadjuvanted: No agents added to, or used in conjunction with, vaccine antigens to augment or potentiate (and possibly target) the specific immune response to the antigen. (U.S. Food And Drug Administration)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroprotection at Day 21 Following Single Administration of Vaccination, Severe Asthmatics</title>
          <description>Percentage of participants with seroprotection defined as hemagglutination inhibition assay (HAI) antibody titer of 1:40 or greater against influenza H1N1 2009 virus following a single administration of the H1N1 vaccine at each dose, combined across age groups.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.9"/>
                    <measurement group_id="O2" value="94.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Seroconversion at Day 28 Following Two Administrations of Vaccination, Mild-Moderate Asthmatics</title>
        <description>Seroconversion: The percentage of participants with a four-fold or greater hemagglutination inhibition assay (HAI) antibody titer increase compared to baseline against the novel influenza hemagglutinin type 1 and neuraminidase type 1 (H1N1) 2009 virus following two administrations of Novartis H1N1 vaccine at each dose, combined across age groups.</description>
        <time_frame>Days 1 to 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mild/Moderate Asthma, Low Dose Vaccine (15mcg)</title>
            <description>Participants with mild-to-moderate asthma received one 15 micrograms (mcg) dose of unadjuvanted[1], inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injection on Day 1 and Day 21.</description>
          </group>
          <group group_id="O2">
            <title>Mild/Moderate Asthma, High Dose Vaccine (30mcg)</title>
            <description>Participants with mild-to-moderate asthma received two 15 mcg doses of unadjuvanted[1], inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injections on Day 1 and Day 21.
[1] Unadjuvanted: No agents added to, or used in conjunction with, vaccine antigens to augment or potentiate (and possibly target) the specific immune response to the antigen. (U.S. Food And Drug Administration)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion at Day 28 Following Two Administrations of Vaccination, Mild-Moderate Asthmatics</title>
          <description>Seroconversion: The percentage of participants with a four-fold or greater hemagglutination inhibition assay (HAI) antibody titer increase compared to baseline against the novel influenza hemagglutinin type 1 and neuraminidase type 1 (H1N1) 2009 virus following two administrations of Novartis H1N1 vaccine at each dose, combined across age groups.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.6"/>
                    <measurement group_id="O2" value="86.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.341</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Seroconversion at Day 28 Following Two Administrations of Vaccination, Severe Asthmatics</title>
        <description>Seroconversion: The percentage of participants with a four-fold or greater hemagglutination inhibition assay (HAI) antibody titer increase compared to baseline against the novel influenza hemagglutinin type 1 and neuraminidase type 1 (H1N1) 2009 virus following two administrations of Novartis H1N1 vaccine at each dose, combined across age groups.</description>
        <time_frame>Days 1 to 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Severe Asthma, Low Dose Vaccine (15mcg)</title>
            <description>Participants with severe asthma received one 15 mcg dose of unadjuvanted[1], inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injection on Day 1 and Day 21.</description>
          </group>
          <group group_id="O2">
            <title>Severe Asthma, High Dose Vaccine (30mcg)</title>
            <description>Participants with severe asthma received two 15 mcg doses of unadjuvanted[1], inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injections on Day 1 and Day 21.
[1] Unadjuvanted: No agents added to, or used in conjunction with, vaccine antigens to augment or potentiate (and possibly target) the specific immune response to the antigen. (U.S. Food And Drug Administration)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion at Day 28 Following Two Administrations of Vaccination, Severe Asthmatics</title>
          <description>Seroconversion: The percentage of participants with a four-fold or greater hemagglutination inhibition assay (HAI) antibody titer increase compared to baseline against the novel influenza hemagglutinin type 1 and neuraminidase type 1 (H1N1) 2009 virus following two administrations of Novartis H1N1 vaccine at each dose, combined across age groups.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.8"/>
                    <measurement group_id="O2" value="85.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.020</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Seroconversion at Day 41 Following Two Administrations of Vaccination, Mild-Moderate Asthmatics</title>
        <description>Seroconversion: The percentage of participants with a four-fold or greater hemagglutination inhibition assay (HAI) antibody titer increase compared to baseline against the novel influenza hemagglutinin type 1 and neuraminidase type 1 (H1N1) 2009 virus following two administrations of Novartis H1N1 vaccine at each dose, combined across age groups.</description>
        <time_frame>Days 1 to 41</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mild/Moderate Asthma, Low Dose Vaccine (15mcg)</title>
            <description>Participants with mild-to-moderate asthma received one 15 micrograms (mcg) dose of unadjuvanted[1], inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injection on Day 1 and Day 21.</description>
          </group>
          <group group_id="O2">
            <title>Mild/Moderate Asthma, High Dose Vaccine (30mcg)</title>
            <description>Participants with mild-to-moderate asthma received two 15 mcg doses of unadjuvanted[1], inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injections on Day 1 and Day 21.
[1] Unadjuvanted: No agents added to, or used in conjunction with, vaccine antigens to augment or potentiate (and possibly target) the specific immune response to the antigen. (U.S. Food And Drug Administration)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion at Day 41 Following Two Administrations of Vaccination, Mild-Moderate Asthmatics</title>
          <description>Seroconversion: The percentage of participants with a four-fold or greater hemagglutination inhibition assay (HAI) antibody titer increase compared to baseline against the novel influenza hemagglutinin type 1 and neuraminidase type 1 (H1N1) 2009 virus following two administrations of Novartis H1N1 vaccine at each dose, combined across age groups.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.8"/>
                    <measurement group_id="O2" value="80.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.245</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Seroconversion at Day 41 Following Two Administrations of Vaccination, Severe Asthmatics</title>
        <description>Seroconversion: The percentage of participants with a four-fold or greater hemagglutination inhibition assay (HAI) antibody titer increase compared to baseline against the novel influenza hemagglutinin type 1 and neuraminidase type 1 (H1N1) 2009 virus following two administrations of Novartis H1N1 vaccine at each dose, combined across age groups.</description>
        <time_frame>Days 1 to 41</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Severe Asthma, Low Dose Vaccine (15mcg)</title>
            <description>Participants with severe asthma received one 15 mcg dose of unadjuvanted[1], inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injection on Day 1 and Day 21.</description>
          </group>
          <group group_id="O2">
            <title>Severe Asthma, High Dose Vaccine (30mcg)</title>
            <description>Participants with severe asthma received two 15 mcg doses of unadjuvanted[1], inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injections on Day 1 and Day 21.
[1] Unadjuvanted: No agents added to, or used in conjunction with, vaccine antigens to augment or potentiate (and possibly target) the specific immune response to the antigen. (U.S. Food And Drug Administration)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion at Day 41 Following Two Administrations of Vaccination, Severe Asthmatics</title>
          <description>Seroconversion: The percentage of participants with a four-fold or greater hemagglutination inhibition assay (HAI) antibody titer increase compared to baseline against the novel influenza hemagglutinin type 1 and neuraminidase type 1 (H1N1) 2009 virus following two administrations of Novartis H1N1 vaccine at each dose, combined across age groups.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.4"/>
                    <measurement group_id="O2" value="82.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.173</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Seroprotection at Day 28 Following Two Administrations of Vaccination, Mild-Moderate Asthmatics</title>
        <description>Seroprotection: The percentage of participants with a hemagglutination inhibition assay (HAI) antibody titer of 1:40 or greater against influenza H1N1 2009 virus following two administrations of the H1N1 vaccine at each dose, combined across age groups.</description>
        <time_frame>Days 1 to 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mild/Moderate Asthma, Low Dose Vaccine (15mcg)</title>
            <description>Participants with mild-to-moderate asthma received one 15 micrograms (mcg) dose of unadjuvanted[1], inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injection on Day 1 and Day 21.</description>
          </group>
          <group group_id="O2">
            <title>Mild/Moderate Asthma, High Dose Vaccine (30mcg)</title>
            <description>Participants with mild-to-moderate asthma received two 15 mcg doses of unadjuvanted[1], inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injections on Day 1 and Day 21.
[1] Unadjuvanted: No agents added to, or used in conjunction with, vaccine antigens to augment or potentiate (and possibly target) the specific immune response to the antigen. (U.S. Food And Drug Administration)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroprotection at Day 28 Following Two Administrations of Vaccination, Mild-Moderate Asthmatics</title>
          <description>Seroprotection: The percentage of participants with a hemagglutination inhibition assay (HAI) antibody titer of 1:40 or greater against influenza H1N1 2009 virus following two administrations of the H1N1 vaccine at each dose, combined across age groups.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.4"/>
                    <measurement group_id="O2" value="91.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.362</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Seroprotection at Day 28 Following Two Administrations of Vaccination, Severe Asthmatics</title>
        <description>Percentage of participants with seroprotection defined as a hemagglutination inhibition assay (HAI) antibody titer of 1:40 or greater against influenza H1N1 2009 virus following two administrations of the H1N1 vaccine at each dose, combined across age groups.</description>
        <time_frame>Days 1 to 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Severe Asthma, Low Dose Vaccine (15mcg)</title>
            <description>Participants with severe asthma received one 15 mcg dose of unadjuvanted[1], inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injection on Day 1 and Day 21.</description>
          </group>
          <group group_id="O2">
            <title>Severe Asthma, High Dose Vaccine (30mcg)</title>
            <description>Participants with severe asthma received two 15 mcg doses of unadjuvanted[1], inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injections on Day 1 and Day 21.
[1] Unadjuvanted: No agents added to, or used in conjunction with, vaccine antigens to augment or potentiate (and possibly target) the specific immune response to the antigen. (U.S. Food And Drug Administration)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroprotection at Day 28 Following Two Administrations of Vaccination, Severe Asthmatics</title>
          <description>Percentage of participants with seroprotection defined as a hemagglutination inhibition assay (HAI) antibody titer of 1:40 or greater against influenza H1N1 2009 virus following two administrations of the H1N1 vaccine at each dose, combined across age groups.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.6"/>
                    <measurement group_id="O2" value="93.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Seroprotection at Day 41 Following Two Administrations of Vaccination, Mild-Moderate Asthmatics</title>
        <description>Percentage of participants with seroprotection defined as a hemagglutination inhibition assay (HAI) antibody titer of 1:40 or greater against influenza H1N1 2009 virus following two administrations of the H1N1 vaccine at each dose, combined across age groups.</description>
        <time_frame>Days 1 to 41</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mild/Moderate Asthma, Low Dose Vaccine (15mcg)</title>
            <description>Participants with mild-to-moderate asthma received one 15 micrograms (mcg) dose of unadjuvanted[1], inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injection on Day 1 and Day 21.</description>
          </group>
          <group group_id="O2">
            <title>Mild/Moderate Asthma, High Dose Vaccine (30mcg)</title>
            <description>Participants with mild-to-moderate asthma received two 15 mcg doses of unadjuvanted[1], inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injections on Day 1 and Day 21.
[1] Unadjuvanted: No agents added to, or used in conjunction with, vaccine antigens to augment or potentiate (and possibly target) the specific immune response to the antigen. (U.S. Food And Drug Administration)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroprotection at Day 41 Following Two Administrations of Vaccination, Mild-Moderate Asthmatics</title>
          <description>Percentage of participants with seroprotection defined as a hemagglutination inhibition assay (HAI) antibody titer of 1:40 or greater against influenza H1N1 2009 virus following two administrations of the H1N1 vaccine at each dose, combined across age groups.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.5"/>
                    <measurement group_id="O2" value="93.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.016</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Seroprotection at Day 41 Following Two Administrations of Vaccination, Severe Asthmatics</title>
        <description>Percentage of participants with seroprotection defined as a hemagglutination inhibition assay (HAI) antibody titer of 1:40 or greater against influenza H1N1 2009 virus following two administrations of the H1N1 vaccine at each dose, combined across age groups.</description>
        <time_frame>Days 1 to 41</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Severe Asthma, Low Dose Vaccine (15mcg)</title>
            <description>Participants with severe asthma received one 15 mcg dose of unadjuvanted[1], inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injection on Day 1 and Day 21.</description>
          </group>
          <group group_id="O2">
            <title>Severe Asthma, High Dose Vaccine (30mcg)</title>
            <description>Participants with severe asthma received two 15 mcg doses of unadjuvanted[1], inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injections on Day 1 and Day 21.
[1] Unadjuvanted: No agents added to, or used in conjunction with, vaccine antigens to augment or potentiate (and possibly target) the specific immune response to the antigen. (U.S. Food And Drug Administration)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroprotection at Day 41 Following Two Administrations of Vaccination, Severe Asthmatics</title>
          <description>Percentage of participants with seroprotection defined as a hemagglutination inhibition assay (HAI) antibody titer of 1:40 or greater against influenza H1N1 2009 virus following two administrations of the H1N1 vaccine at each dose, combined across age groups.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0"/>
                    <measurement group_id="O2" value="89.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.032</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Enrollment through last day of followup (Day 201, target last day)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Mild/Moderate Asthma, Low Dose Vaccine (15 Mcg)</title>
          <description>Participants with mild/moderate asthma received one 15 mcg dose of unadjuvanted, inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injection on Day 1 and Day 21.</description>
        </group>
        <group group_id="E2">
          <title>Mild/Moderate Asthma, High Dose Vaccine (30mcg)</title>
          <description>Participants with mild/moderate asthma received two 15 mcg doses of unadjuvanted, inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injection on Day 1 and Day 21.</description>
        </group>
        <group group_id="E3">
          <title>Severe Asthma, Low Dose Vaccine (15mcg)</title>
          <description>Participants with severe asthma received one 15 mcg dose of unadjuvanted, inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injection on Day 1 and Day 21.</description>
        </group>
        <group group_id="E4">
          <title>Severe Asthma, High Dose Vaccine (30mcg)</title>
          <description>Participants with severe asthma received two 15 mcg doses of unadjuvanted, inactivated Novartis H1N1 pandemic influenza vaccine by intramuscular injection on Day 1 and Day 21.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="87"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Drug rehabilitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Hysterectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="110"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="107"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="87"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Forced expiratory volume decreased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E3" events="9" subjects_affected="7" subjects_at_risk="87"/>
                <counts group_id="E4" events="13" subjects_affected="8" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="110"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="87"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="110"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" events="7" subjects_affected="5" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Associate Director, Clinical Research Program</name_or_title>
      <organization>DAIT/NIAID</organization>
      <phone>301-594-7669</phone>
      <email>DAITClinicalTrialsGov@niaid.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

